ArticleEuropean radiology2026
Can ADC differentiate cellular from acellular mucin in mucinous adenocarcinoma tumor beds after treatment of rectal cancer? A multicenter study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine if the apparent diffusion coefficient (ADC) can distinguish acellular mucin from cellular mucin in the treated tumor bed of patients with mucinous rectal adenocarcinoma after neoadjuvant therapy. MATERIALS AND
methodsThis retrospective study included patients with mucinous rectal adenocarcinoma treated with neoadjuvant therapy, followed by restaging MRI and surgical resection or biopsy. Three radiologists blinded to histopathology results independently segmented volumes of interest on diffusion-weighted imaging and ADC maps. A medical physicist performed histogram analysis of ADC map segmentations, calculating various ADC metrics: mean, standard deviation, median, 1st quartile, 2nd quartile, 3rd quartile, and 4th quartile. The Wilcoxon rank sum test with false discovery rate correction for multiple testing was used to examine associations between ADC metrics and tumor mucin cellularity at histopathology for each reader. Multivariable logistic regression was used to adjust for acquisition parameters and institutions.
resultsOf 150 patients (mean age, 58 ± 14 years; 48/150 (32% female), 25 patients (17%) had acellular mucin and 125 (83%) had cellular mucin at histopathology. At univariable analysis, there was no significant association between any ADC metric and tumor mucin cellularity (q-value = 0.14-0.58). At multivariable analysis, most ADC metrics were significantly associated with tumor mucin cellularity for all readers (q-values = 0.016-0.025) with odds ratios between 0.09 (95% CI: 0.02, 0.42) and 0.49 (95% CI: 0.22, 0.96).
conclusionsADC may be a potential tool for assessing pathologic complete response in mucinous rectal adenocarcinoma after neoadjuvant treatment, after adjusting for acquisition parameters and institutions. KEY POINTS: QuestionCan the apparent diffusion coefficient (ADC) distinguish between cellular and acellular mucin (i.e., pathologic complete response) in mucinous rectal adenocarcinoma after neoadjuvant therapy? FindingsAfter controlling for acquisition parameters, ADC metrics were significantly associated with tumor mucin cellularity. Clinical relevanceAcellular mucin is equivalent to clinical complete response and can undergo watch-and-wait management, whereas cellular mucin is incomplete response, and its safety for watch-and-wait management is not validated. ADC may be a potential tool to make the distinction to assist treatment decision-making.
Indexed as
Identifiers
41832931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.